MoonLake Immunotherapeutics - 8-K Filing
MoonLake Immunotherapeutics reported Week 52 results for its Phase 3 VELA trials (VELA-1 and VELA-2) of sonelokimab (SLK), showing that 67.2% of patients achieved HiSCR75, with 33.1% achieving HiSCR100 at Week 52 across both studies. Additionally, 26.0% reached inflammatory remission as measured by IHS4-100. The company also shared interim data from the VELA-TEEN trial in adolescents showing ~68% achieved HiSCR75 and ~45% achieved HiSCR100 at Week 24, with no new safety signals observed across all trials. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $MLTX